Difficulty: Medium
Average Score: 76%
Testbank
The nurse is caring for a patient in acute kidney injury. Which of the following complications would most clearly warrant the administration of polystyrene sulfonate (Kayexalate)?
Correct answer
C
Rationale
C: Hyperkalemia
Polystyrene sulfonate (Kayexalate) is specifically indicated for the treatment of hyperkalemia, a common complication in acute kidney injury due to the kidneys' reduced ability to excrete potassium. Administering Kayexalate helps to lower elevated potassium levels, thereby preventing potentially life-threatening cardiac complications.
A: Hypernatremia
Hypernatremia is characterized by elevated sodium levels, which are not directly addressed by polystyrene sulfonate, making this option irrelevant to the treatment of acute kidney injury.
B: Hypomagnesemia
Hypomagnesemia refers to low magnesium levels, and while it may occur in kidney injury, it is not treated with polystyrene sulfonate, thus making this option unsuitable for the scenario presented.
D: Hypercalcemia
Hypercalcemia involves elevated calcium levels, which Kayexalate does not target. Therefore, this option does not relate to the primary concern of managing potassium levels in acute kidney injury.
Polystyrene sulfonate (Kayexalate) is specifically indicated for the treatment of hyperkalemia, a common complication in acute kidney injury due to the kidneys' reduced ability to excrete potassium. Administering Kayexalate helps to lower elevated potassium levels, thereby preventing potentially life-threatening cardiac complications.
A: Hypernatremia
Hypernatremia is characterized by elevated sodium levels, which are not directly addressed by polystyrene sulfonate, making this option irrelevant to the treatment of acute kidney injury.
B: Hypomagnesemia
Hypomagnesemia refers to low magnesium levels, and while it may occur in kidney injury, it is not treated with polystyrene sulfonate, thus making this option unsuitable for the scenario presented.
D: Hypercalcemia
Hypercalcemia involves elevated calcium levels, which Kayexalate does not target. Therefore, this option does not relate to the primary concern of managing potassium levels in acute kidney injury.